Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142923 | 0.86 | NSD2 (0.42) | — | |
| SCHEMBL3135510 | 0.84 | GRM2 (0.50) | GRM2 | |
| SCHEMBL7842308 | 0.82 | TAAR1 (0.57) | ALDH1A1TAAR1GRM2 | |
| SCHEMBL3144469 | 0.82 | RAB9A (0.42) | ALDH1A1GRM2 | |
| SCHEMBL3148324 | 0.81 | DRD4 (0.39) | ALDH1A1 | |
| SCHEMBL3135569 | 0.78 | PARP15 (0.40) | KDM4EGRM2 | |
| SCHEMBL3148352 | 0.78 | ALOX15 (0.43) | ALDH1A1 | |
| SCHEMBL3138790 | 0.78 | SMN1; SMN2 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL1513582 | 0.78 | TSHR (0.41) | ALDH1A1GRM2 | |
| SCHEMBL27778759 | 0.78 | ALOX5 (0.39) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503695-B2 | RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-12-23 | — | — | US | disclosed |
| CN-120006265-A | Copper-based chemical nickel plating method | 厦门大学 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025072713-A1 | POLYMYXINS FOR DELIVERY OF AGENTS TO THE KIDNEY | JUDO BIO, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| WO-2025072699-A1 | AMINOGLYCOSIDES FOR DELIVERY OF AGENTS TO THE KIDNEY | JUDO BIO, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4499712-A2 | TARGETED DELIVERY | Judo Bio Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4472997-A2 | TARGETING MOIETIES PROMOTING TRANSDUCTION OF CENTRAL NERVOUS SYSTEM CELLS AND TISSUES AND METHODS OF USE | The Broad Institute, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-119101089-A | Oligonucleotide synthesis process of chimeric PMO structure | 苏州盛诺维生物科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118988400-A | Efficient and stable catalyst and preparation method and application thereof | 浙江大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118616096-B | Alumina-supported composite catalyst and preparation method and application thereof | 浙江大学 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023183628-A2 | TARGETED DELIVERY | JUDO BIO INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023150632-A2 | TARGETING MOIETIES PROMOTING TRANSDUCTION OF CENTRAL NERVOUS SYSTEM CELLS AND TISSUES AND METHODS OF USE | THE BROAD INSTITUTE, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-110909787-B | Method and system for optimizing multi-target batch scheduling based on cluster evolution algorithm | 安徽大学 | 2023-05-12 | — | — | CN | disclosed |
| US-20230057461-A1 | RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-23 | — | — | US | disclosed |
| JP-2022071540-A | RADIO COMMUNICATION SYSTEM, ADMINISTRATIVE SERVER AND COMMUNICATION METHOD | 日本電信電話株式会社 | 2022-05-16 | — | — | JP | disclosed |
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | disclosed |
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | disclosed |
| US-4499090-A | N-(5-aminomethyl-2-oxazolin-2-yl)-N'-phenylureas, compositions and use | SOCIETE CORTIAL, S.A. (FR) | 1985-02-12 | — | — | US | disclosed |
| US-4497812-A | ANTIHISTIMINES;ANTINFLAMMATORY AGENTS;ANTIALLERGENS;DIURETICS;CARDIOVASCULAR THERAPY | SOCIETE CORTIAL, S.A. (FR) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | KDM4E 1354/4885ALDH1A1 1875/4885TAAR1 284/4885 |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | KDM4E 2667/4885ALDH1A1 4524/4885TAAR1 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.